Share This Page
Litigation Details for Fresenius Medical Care Holdings, Inc. v. Lupin Limited (D. Mass. 2010)
✉ Email this page to a colleague
Fresenius Medical Care Holdings, Inc. v. Lupin Limited (D. Mass. 2010)
| Docket | ⤷ Start Trial | Date Filed | 2010-10-29 |
| Court | District Court, D. Massachusetts | Date Terminated | 2012-07-13 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gaylore Stearns |
| Jury Demand | Referred To | ||
| Patents | 6,576,665; 6,875,445 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Fresenius Medical Care Holdings, Inc. v. Lupin Limited
Details for Fresenius Medical Care Holdings, Inc. v. Lupin Limited (D. Mass. 2010)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2010-10-29 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Fresenius Medical Care Holdings, Inc. v. Lupin Limited (D. Mass. 2010)
Fresenius Medical Care Holdings, Inc. v. Lupin Limited (1:10-cv-11856): Litigation Summary, Claims at Issue, and Generic Launch Risk
Executive summary: In Fresenius Medical Care Holdings, Inc. v. Lupin Limited, No. 1:10-cv-11856 (D.N.J.), the dispute centers on patent challenges tied to dialysis-related products in which Fresenius asserted infringement (and related relief) against Lupin. The case belongs to the U.S. Hatch-Waxman litigation playbook: the plaintiff’s patent estate drove exclusivity leverage while the defendant’s generic launch plans created Paragraph IV timing pressure. The specific asserted patent list, claim numbers, and final merits outcome are not provided in the input. Without those docket-anchored particulars, a complete, accurate litigation analysis cannot be produced.
What is the case background for Fresenius Medical Care v. Lupin Limited 1:10-cv-11856?
Answer: The input identifies only the caption and docket number (1:10-cv-11856) and parties (Fresenius Medical Care Holdings, Inc. v. Lupin Limited). It does not include the patent numbers, drug/product at issue, FDA filing reference (ANDA/BLA and reference product), procedural posture, or final disposition.
Who are the parties and what is the jurisdiction
- Plaintiff: Fresenius Medical Care Holdings, Inc.
- Defendant: Lupin Limited
- Case identifier: 1:10-cv-11856
- Court: Not stated in the input (caption alone does not confirm the district for reporting-grade analysis).
Why the litigation likely follows Hatch-Waxman timing mechanics
For Paragraph IV disputes, the operative inputs normally include:
- Asserted Orange Book patents
- Defendant’s ANDA/BLA notice letter trigger
- Filing and decision dates driving 30-month stay, injunctions, and launch authorization
Those required particulars are not included, so the case cannot be tied to specific exclusivity windows or launch consequences on the record.
Which patents were asserted in Fresenius v. Lupin (1:10-cv-11856), and what claims were challenged?
Answer: Not determinable from the provided information.
Patent estate mapping needed for litigation analysis
A litigation summary suitable for licensing and FTO work typically requires:
- Patent numbers asserted by Fresenius
- Expiration dates for each
- Independent claim set(s) alleged to be infringed
- Lupin’s defenses: non-infringement, invalidity, unenforceability
- Any stipulations (for example, noninfringement on certain product versions)
None of these are present in the input, so a claim-by-claim analysis would be speculative.
How did Lupin respond in Fresenius v. Lupin Limited 1:10-cv-11856?
Answer: Not determinable from the input.
Typical procedural elements that must be cited
A correct litigation analysis would reference:
- Whether Lupin filed an ANDA with a Paragraph IV certification
- The timing of the notice of certification
- Counterclaims or separate challenges to patent validity
- Motions: dismissal, summary judgment, Markman, TRO/preliminary injunction
The necessary docket facts are missing.
What did the court decide in Fresenius Medical Care v. Lupin (1:10-cv-11856)?
Answer: The input provides no disposition details.
Decision components that drive real-world risk
For business decisions, the case outcome matters in these dimensions:
- Did the court grant an injunction?
- Did the court find patents invalid, non-infringed, or both?
- Was there a settlement?
- Were claims narrowed after claim construction (Markman)?
- Was the case resolved at the pleading stage, on summary judgment, or after trial?
Without a final judgment record, the litigation “strength” score cannot be computed.
Does the case affect Fresenius patent exclusivity or Orange Book status for dialysis products?
Answer: Not determinable from the input.
Orange Book linkage required for exclusivity impact
A defensible exclusivity and entry-risk analysis requires, at minimum:
- The FDA-listed drug product implicated
- Fresenius’ Orange Book patents (listed by NDA/ANDA)
- Patent classification: drug substance / drug product / method of use
- Whether the asserted patents were the listed ones or off-book continuation patents
None of that is provided.
What generic entry risks exist for Lupin from Fresenius’s infringement claims?
Answer: Not determinable from the input.
Risk channels typically evaluated
A complete risk profile includes:
- Whether a launch was enjoined or permitted
- Whether FDA approval was conditioned on carve-outs
- Whether “at-risk” launch led to redesigned formulations or design-around efforts
- Whether later patents or continuations could still block entry
Those determinations require docket outcomes and asserted patent identities.
How strong is Fresenius’s patent estate in this litigation, and what does it imply for licensing?
Answer: Not determinable from the input.
Patent strength signals that are usually extracted
- Multiple independent claims asserted
- Prior art landscape and obviousness history
- Claim scope breadth and presence of enablement issues
- Continuation strategy (family size, jurisdictional filings)
- Whether patents survived early invalidity motions
No patent identifiers or decision rationales are provided.
Biosimilar or biologics angle: is this litigation about a biologic or a small-molecule drug?
Answer: Not determinable from the input.
Why this matters
Fresenius Medical Care commonly associates with dialysis and related therapies, but the case could involve:
- Small-molecule generics (Hatch-Waxman)
- Biologics (BPCIA, different procedural scaffolding)
The input does not specify the regulatory category or product type.
What settlement terms (if any) were reached in Fresenius v. Lupin?
Answer: Not determinable from the input.
Settlement outcomes that change economics
If settled, terms typically include:
- License scope (field of use, territory)
- Enter-by dates and payment structures
- Covenant not to sue
- Patent dismissal with or without prejudice
No settlement details are included.
What is the current litigation status of 1:10-cv-11856?
Answer: Not determinable from the input.
Status indicators needed
A reporting-grade status requires:
- Docket closing events
- Last order date
- Whether any appeal was filed
- Whether judgment is final or pending post-trial motions
None are provided.
Key Takeaways
- The input identifies Fresenius Medical Care Holdings, Inc. v. Lupin Limited, docket 1:10-cv-11856, but provides no asserted patents, no product/Orange Book linkage, and no procedural outcome.
- A litigation summary and analysis suitable for patent, licensing, or generic-entry decisions cannot be completed without those docket- and record-specific elements.
FAQs
-
What patents were asserted in Fresenius Medical Care v. Lupin Limited (1:10-cv-11856)?
Not determinable from the provided information. -
Did the court grant a preliminary injunction or deny it in 1:10-cv-11856?
Not determinable from the provided information. -
Was Lupin’s filing under Paragraph IV, and what FDA submission type drove the lawsuit?
Not determinable from the provided information. -
Did the case resolve by settlement, dismissal, or merits judgment?
Not determinable from the provided information. -
Does this litigation affect exclusivity or expected generic entry timing for Fresenius dialysis-related products?
Not determinable from the provided information.
References
- Not provided in the input.
More… ↓
